Chromosome 9p24 abnormalities: Prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates

European Journal of Haematology

Volumn 84, Issue 6, 2010, Pages 518-524

  Patnaik, Mrinal M ^a   Knudson, Ryan A ^a   Gangat, Naseema ^a   Hanson, Curtis A ^a   Pardanani, Animesh ^a   Tefferi, Ayalew ^a   Ketterling, Rhett P ^a  

^a MAYO CLINIC   (United States)

Author keywords

9p24; Amplification; Chromosome; Cytogenetic; JAK2; Karyotype; Mutation

Indexed keywords

BUSULFAN; CYTARABINE; ETOPOSIDE; JANUS KINASE 2; MELPHALAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BONE MARROW; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CHROMOSOME 9P; CHROMOSOME ABERRATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CYTOGENETICS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DISRUPTION; GENE MUTATION; GENE STRUCTURE; GENE TRANSLOCATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC DATABASE; HUMAN; KARYOTYPE; MALE; MANTLE CELL LYMPHOMA; MORPHOLOGY; MULTIPLE MYELOMA; MUTATIONAL ANALYSIS; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REFRACTORY ANEMIA WITH EXCESS BLASTS; STRUCTURE ANALYSIS;

AGED; AMINO ACID SUBSTITUTION; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 9; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; JANUS KINASE 2; KARYOTYPING; LEUKEMIA; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MUTATION, MISSENSE; MYELOPROLIFERATIVE DISORDERS; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; RETROSPECTIVE STUDIES; TRANSLOCATION, GENETIC;

EID: 77952614673     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2010.01428.x     Document Type: Article

References (38)

1. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005 434: 1144 1148. (Pubitemid 40663494) (Pubitemid 40663494)
2. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005 352: 1779 1790. (Pubitemid 40570926) (Pubitemid 40570926)
3. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005 7: 387 397.
4. Renneville A, Quesnel B, Charpentier A, et al. High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Leukemia 2006 20: 2067 2070.
5. Steensma DP, McClure RF, Karp JE, Tefferi A, Lasho TL, Powell HL, DeWald GW, Kaufmann SH, JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained. Leukemia 2006 20: 971 978.
6. Verstovsek S, Silver RT, Cross NC, Tefferi A. JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less? Leukemia 2006 20: 2067.
7. Vizmanos JL, Ormazabal C, Larrayoz MJ, Cross NC, Calasanz MJ. JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report on a series of 349 patients. Leukemia 2006 20: 534 535.
8. Lacronique V, Boureux A, Valle VD, et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 1997 278: 1309 1312.
9. Peeters P, Raynaud SD, Cools J, et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 1997 90: 2535 2540.
10. Griesinger F, Hennig H, Hillmer F, Podleschny M, Steffens R, Pies A, Wormann B, Haase D, Bohlander SK. A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia. Genes Chromosomes Cancer 2005 44: 329 333.
11. Adelaide J, Perot C, Gelsi-Boyer V, Pautas C, Murati A, Copie-Bergman C, Imbert M, Chaffanet M, Birnbaum D, Mozziconacci MJ. A t(8;9) translocation with PCM1-JAK2 fusion in a patient with T-cell lymphoma. Leukemia 2006 20: 536 537.
12. Bousquet M, Quelen C, De Mas V, Duchayne E, Roquefeuil B, Delsol G, Laurent G, Dastugue N, Brousset P. The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene. Oncogene 2005 24: 7248 7252.
13. Murati A, Gelsi-Boyer V, Adelaide J, et al. PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation. Leukemia 2005 19: 1692 1696.
14. Reiter A, Walz C, Watmore A, et al. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res 2005 65: 2662 2667.
15. Poitras JL, Dal Cin P, Aster JC, Deangelo DJ, Morton CC. Novel SSBP2-JAK2 fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre-B acute lymphocytic leukemia. Genes Chromosomes Cancer 2008 47: 884 889.
16. Mark HF, Sotomayor EA, Nelson M, Chaves F, Sanger WG, Kaleem Z, Caughron SK. Chronic idiopathic myelofibrosis (CIMF) resulting from a unique 3;9 translocation disrupting the janus kinase 2 (JAK2) gene. Exp Mol Pathol 2006 81: 217 223.
17. Najfeld V, Cozza A, Berkofsy-Fessler W, Prchal J, Scalise A. Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and-negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms. Exp Hematol 2007 35: 1668 1676.
18. Nebral K, Denk D, Attarbaschi A, Konig M, Mann G, Haas OA, Strehl S. Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia. Leukemia 2009 23: 134 143.
19. Bentz M, Barth TF, Bruderlein S, et al. Gain of chromosome arm 9p is characteristic of primary mediastinal B-cell lymphoma (MBL): comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line. Genes Chromosomes Cancer 2001 30: 393 401.
20. Joos S, Kupper M, Ohl S, et al. Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res 2000 60: 549 552.
21. Helias C, Struski S, Gervais C, Leymarie V, Mauvieux L, Herbrecht R, Lessard M. Polycythemia vera transforming to acute myeloid leukemia and complex abnormalities including 9p homogeneously staining region with amplification of MLLT3, JMJD2C, JAK2, and SMARCA2. Cancer Genet Cytogenet 2008 180: 51 5.
22. Pardanani A, Ketterling RP, Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003 102: 3093 3096.
23. Brockman SR, Paternoster SF, Ketterling RP, Dewald GW. New highly sensitive fluorescence in situ hybridization method to detect PML/RARA fusion in acute promyelocytic leukemia. Cancer Genet Cytogenet 2003 145: 144 151.
24. Kittur J, Knudson RA, Lasho TL, et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer 2007 109: 2279 2284.
25. Tanner SM, Austin JL, Leone G, et al. BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia. Proc Natl Acad Sci USA 2001 98: 13901 13906.
26. Taviaux S, Brunel V, Dupont M, Fernandez F, Ferraz C, Carbuccia N, Sainty D, Demaille J, Birg F, Lafage-Pochitaloff M. Simple variant t(8;21) acute myeloid leukemias harbor insertions of the AML1 or ETO genes. Genes Chromosomes Cancer 1999 24: 165 171.
27. Erickson P, Gao J, Chang KS, Look T, Whisenant E, Raimondi S, Lasher R, Trujillo J, Rowley J, Drabkin H. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. Blood 1992 80: 1825 1831.
28. Nucifora G, Birn DJ, Erickson P, Gao J, LeBeau MM, Drabkin HA, Rowley JD. Detection of DNA rearrangements in the AML1 and ETO loci and of an AML1/ETO fusion mRNA in patients with t(8;21) acute myeloid leukemia. Blood 1993 81: 883 888.
29. Wang HY, Tirado CA. t(8;21)(q22;q22) Translocation involving AML1 and ETO in B lymophoblastic leukemia. Hum Pathol 2010 41: 286 292.
30. Baldus CD, Tanner SM, Ruppert AS, et al. BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. Blood 2003 102: 1613 1618.
31. Walz C, Chase A, Schoch C, et al. The t(8;17)(p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to FGFR1. Leukemia 2005 19: 1005 1009.
32. Suzuki A, Kusakai G, Kishimoto A, Shimojo Y, Miyamoto S, Ogura T, Ochiai A, Esumi H. Regulation of caspase-6 and FLIP by the AMPK family member ARK5. Oncogene 2004 23: 7067 7075.
33. Drieschner N, Kerschling S, Soller JT, Rippe V, Belge G, Bullerdiek J, Nimzyk R. A domain of the thyroid adenoma associated gene (THADA) conserved in vertebrates becomes destroyed by chromosomal rearrangements observed in thyroid adenomas. Gene 2007 403: 110 117.
34. Meloni-Ehrig A, Smith B, Zgoda J, Greenberg J, Perdahl-Wallace E, Zaman S, Mowrey P. Translocation (2;8)(q35;q13): a recurrent abnormality in congenital embryonal rhabdomyosarcoma. Cancer Genet Cytogenet 2009 191: 43 5.
35. Plo I, Nakatake M, Malivert L, de Villartay JP, Giraudier S, Villeval JL, Wiesmuller L, Vainchenker W. JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. Blood 2008 112: 1402 1412.
36. Scott LM, Scott MA, Campbell PJ, Green AR. Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood 2006 108: 2435 2437.
37. Passamonti F, Rumi E, Pietra D, et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood 2006 107: 3676 3682.
38. Slupianek A, Hoser G, Majsterek I, Bronisz A, Malecki M, Blasiak J, Fishel R, Skorski T. Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis. Mol Cell Biol 2002 22: 4189 4201.